For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,565,244 | 2,878,529.5* | 2,177,922 | 2,764,805 |
| General and administrative | 3,140,712 | 2,454,900* | 3,294,456 | 3,204,072 |
| Total operating expenses | 5,705,956 | 5,333,429.5 | 5,472,378 | 5,968,877 |
| Loss from operations | -5,705,956 | -5,333,429.5* | -5,472,378 | -5,968,877 |
| Change in estimated fair value of warrant liability | - | 0* | 0 | 0 |
| Gain on settlement of warrants | - | 0* | 0 | - |
| Loss on issuance of related party convertible notes payable at fair value | - | 0* | 0 | 0 |
| Change in estimated fair value of related party convertible notes payable | - | 0* | 0 | 0 |
| Interest expense | 5,062 | 5,062.5* | 5,063 | 5,062 |
| Interest income | 85,269 | 145,952.5* | 69,971 | 24,534 |
| Total other income, net | 80,207 | 140,890* | 64,908 | 19,472 |
| Net loss | -5,625,749 | -5,192,539.5 | -5,407,470 | -5,949,405 |
| Basic EPS | -0.24 | -0.236 | -0.25 | -0.3 |
| Diluted EPS | -0.24 | -0.236 | -0.25 | -0.3 |
| Basic Average Shares | 23,537,134 | 22,024,011 | 21,394,965 | 19,646,475 |
| Diluted Average Shares | 23,537,134 | 22,024,011 | 21,394,965 | 19,646,475 |
ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC. (ACTU)